Variable | Drug allocation | Total, N = 40 | |
---|---|---|---|
Placebo, n = 20 | Primaquine, n = 20 | ||
Age in year, mean (95% CI) | 31.7 (24.4–39.0) | 23.4 (17.1–29.6) | 27.5 (22.6–32.4) |
Male (%) | 14 (70) | 12 (60) | 26 (65) |
Weight kg, mean (95% CI) | 44.5 (39.7–49.3) | 44.6 (38.2–50.9) | 44.5 (40.6–48.5) |
Complete 12-month FU (%) | 16 (80) | 16 (80) | 32 (80) |
Hba g/dl, mean (95% CI) | 13.7 (13.1–14.4) | 13.5 (12.9–14.1) | 13.6 (13.2–14.1) |
Age in year, median (Range) | 32.5 (10–76) | 19 (10–54) | 25.5 (10–76) |
Weight kg, mean (95% CI) | 44.5 (39.7–49.3) | 44.6 (38.2–50.9) | 44.5 (40.6–48.5) |
Recruitment year, n | |||
 Jun-16 | 9 | 9 | 18 |
 Jun-17 | 11 | 11 | 22 |
uPCR | |||
 During surveys of MDA trial | |||
  Mono-PV infection | 16 | 17 | 33 |
  Mixed PV infection | 4 | 3 | 7 |
 At day 0 | |||
  PV infection | 0 | 0 | 0 |